Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07236476 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Identify Effective Doses of LY01021 in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoing Assisted Reproductive Technology (ART)

Name: Identify Effective Doses of LY01021 in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoing Assisted Reproductive Technology (ART) — clinical trial record (NCT07236476)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 2

SponsorLuye Pharma Group Ltd.

Started2024-10-09

View on ClinicalTrials.gov ↗

Record status

This record was last updated November 19, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Luye Pharma Group Ltd.

16 trials monitored

See all monitored trials

This is a multicentre, open-label, dose-finding, phase 2 study that will recruit approximately 90 female subjects undergoing COH for in vitro fertilization (IVF) or intracytoplasmic single sperm injection (ICSI). Three LY01021 dose groups of 40 mg QD, 30 mg QD, and 20 mg QD will be included, with not exceed 45 subjects in each group to investigate the efficacy and safety.

Trial Details

NCT Number	NCT07236476
Lead Sponsor	Luye Pharma Group Ltd.
Conditions	Assisted Reproduction
Enrollment	90 participants
Start Date	2024-10-09
Primary Completion	2025-12-31 (estimated)
Study Completion	2025-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-11-19